Filing summary
Company and period: The supplied 10-K is for REPRO-MED SYSTEMS, INC. (the company identified in the request as KORU Medical Systems, Inc.). It reports the fiscal year ended February 29, 2012, compared with the year ended February 28, 2011—not a standalone 2011 Q4 report. The company designs and sells medical devices, principally the FREEDOM60 infusion system and RES-Q-VAC portable suction system.
Financial performance
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Net sales | $6.391 million | $4.921 million |
| Gross margin | 64.8% | 66.3% |
| Net operating profit | $1.289 million | $1.195 million |
| Income before taxes | $1.281 million | $1.193 million |
| Net income | $815,893 | $704,085 |
| Basic and diluted EPS | $0.02 | $0.02 |
| Cash from operations | $560,601 | $1.028 million |
- Sales increased 29.9%. FREEDOM60-related sales rose 31.9% to $5.333 million; RES-Q-VAC sales fell 8% to $803,200, partly because a large international order in FY 2011 did not recur. Infusion therapy grew to 86.37% of sales from 81.69%.
- Net income increased 15.9%, while operating profit increased 7.9%. Gross margin declined 1.5 percentage points, which management attributed primarily to higher raw-material and production costs. SG&A increased $688,251 to $2.656 million; R&D increased to $90,329.
- Cash and cash equivalents were $1.757 million at year-end, with certificates of deposit of $255,228. Current assets were $4.254 million and current liabilities $558,853. Accounts receivable rose to $884,727 and inventory to $1.167 million from $713,906 and $668,200, respectively.
- Total liabilities were $1.254 million. Notes payable totaled approximately $482,800, including a $479,249 related-party director loan bearing 6% interest and maturing in 2021. Capital expenditures were $236,235. Cash increased $434,973 during the year.
Changes, outlook and risks
- Management attributed the infusion growth to immune globulin, antibiotics and RMS High-Flo subcutaneous needle sets. U.S. FDA marketing approval for the needle sets was received in May 2011; the company also reported European and Canadian approvals.
- Management expected the subcutaneous immune-globulin market to continue expanding and stated it believed available capital and operating trends would cover liquidity needs for the next 12 months. This is management’s outlook, not a quantified sales or earnings forecast.
- Key risks identified include Medicare and other reimbursement changes, FDA and other regulatory requirements, competitive products, market acceptance and expansion, access to capital, patent protection, and dependence on CEO Andrew Sealfon. The company noted it had no life insurance on him. It also cited possible supply constraints from tooling or sourcing changes, although parts availability had not been a problem.
- The company leases its sole headquarters and manufacturing facility under a 20-year lease; disclosed minimum future rent was $927,528. Related-party matters include the director loan, a building owner who is also a director, and aircraft leasing from a company controlled by the CEO.
- The auditor changed in October 2011. The outgoing auditor’s prior reports were not qualified, and the filing reports no disagreements or reportable events. The FY 2012 auditor issued an unqualified opinion. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal control.
Important facts to verify
- Confirm the intended issuer and reporting period: this filing names REPRO-MED SYSTEMS, INC. and covers FY 2012, despite the request metadata identifying KORU Medical Systems and “2011 Q4.”
- Review the FY 2012 cash-flow decline and working-capital build, particularly the $499,256 increase in inventory, against sales and future demand.
- Reconcile apparent inconsistencies in the filing: the tax reconciliation gives FY 2012 income before tax of $1,300,573, versus $1,281,184 in the statements of operations; the balance-sheet comparative heading also appears misstated.
- Assess related-party debt and leases, reimbursement exposure, and the company’s dependence on key personnel and continued growth in the infusion business.